Forma Therapeutics Holdings, Inc.

Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing groundbreaking therapies for rare hematologic conditions and various cancers. Its lead development candidates include FT-4202, undergoing Phase 1 trials for sickle cell disease and other hemoglobinopathies, and FT-7051, targeting metastatic castration-resistant prostate cancer. The company is also progressing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 (IDH1) gene mutations, currently in Phase II for relapsed/refractory acute myeloid leukemia and Phase I for glioma. Furthermore, Forma is developing FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to disrupt de novo lipogenesis in the liver. Founded in 2007 and headquartered in Watertown, Massachusetts, Forma Therapeutics Holdings, Inc. has operated as a subsidiary of Novo Nordisk A/S since October 14, 2022.